Swiss drugmaker Novartis on Friday stepped up its challenge to Roche's mult...
ZURICH - Swiss drugmaker Novartis on Friday stepped up its challenge to Roche’s multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with its cross-town rival’s drug Ocrevus.
The company’s real target with ofatumumab is Ocrevus, the $2.4 billion-per-year MS blockbuster that Roche has said is its most successful drug launch ever. “If approved, ofatumumab will potentially become a treatment for a broad RMS population and the first B-cell therapy that can be self-administered at home,” said Novartis. The company is also repurposing Arzerra for MS as it seeks to strengthen its neurological drugs business, which already includes older MS drugs Gilenya and recently approved Mayzent.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Strengthening Hurricane Dorian takes aim at Bahamas and FloridaHurricane Dorian took aim at the Bahamas and the Florida coast on Thursday, spur...
Leer más »
Hurricane Dorian gains might as it takes aim at FloridaHurricane Dorian churned in the Atlantic, picking up speed early on Thursday, fu...
Leer más »
'BH90210' Recap: Breaking Down What's Fact or Fiction as Reboot Goes Up In FlamesFind out who really lied to land a role on the original show, who's making what and how the new episode took aim at Jussie Smollet's 'Empire' drama.
Leer más »
Live updates: Hurricane Dorian takes aim at Florida, may make landfall as Category 3STORM WATCH: We're tracking Hurricane Dorian as it moves toward Florida coast. FULL FORECAST:
Leer más »
Live updates: Hurricane Dorian takes aim at Florida, may make landfall as Category 4LATEST: Hurricane Dorian may make landfall as a powerful Category 4 on Monday morning. Florida Gov. Ron DeSantis has declared a state of emergency for counties in Dorian's path.
Leer más »